Imidazoles Patents (Class 514/396)
  • Patent number: 11903928
    Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: February 20, 2024
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Yael Rosen, David Dangoor, Richard Fisher
  • Patent number: 11738023
    Abstract: The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 29, 2023
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen C. Harris, Ram P. Kapil, Donald J. Kyle, Garth Whiteside
  • Patent number: 11701335
    Abstract: Methods of normalizing amino acid metabolism in subjects on restricted protein diets and supplemental amino acids, using specially formulated amino acids that mimic the absorption and metabolism of naturally occurring proteins, are described.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: July 18, 2023
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Alberto Reiner, Giorgio Reiner
  • Patent number: 11541062
    Abstract: Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 3, 2023
    Assignee: CITY OF HOPE
    Inventors: Zijie Sun, David Horne, Junfeng Li, John E. Shively, Jun Xie
  • Patent number: 11541036
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
    Type: Grant
    Filed: April 25, 2022
    Date of Patent: January 3, 2023
    Assignee: RVL PHARMACEUTICALS, INC.
    Inventors: Tina Devries, David Jacobs
  • Patent number: 11419335
    Abstract: The present invention provides novel compounds of Formula (I?) and (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for killing a microorganism (e.g., bacteria, fungi, viruses, protozoa, or multicellular parasites), the prevention and/or treatment of infectious diseases (e.g., infections by microorganisms, bacterial infection, cystic fibrosis infection, foreign body infection, urinary tract infection (UTI), or infections leading to biofilms), controlling and/or eradicating biofilms (e.g., bacterial biofilms), preventing biofilm formation, sterilizing a surface, and/or eradicating persister cells (e.g., in a subject in need thereof or in a subject involving a biofilm).
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 23, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Robert William Huigens, III, Yasmeen Abouelhassan, Akash Basak
  • Patent number: 11419837
    Abstract: Methods and formulations of modified release amino acids are provided for the treatment or management of diseases defined by impaired amino acid metabolism, with improved pharmacokinetics, metabolism and utilization.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 23, 2022
    Assignee: APR Applied Pharma Research S.A.
    Inventors: Alberto Reiner, Giorgio Reiner
  • Patent number: 11324722
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: May 10, 2022
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 11311515
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
    Type: Grant
    Filed: August 30, 2021
    Date of Patent: April 26, 2022
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina Devries, David Jacobs
  • Patent number: 11299464
    Abstract: Provided herein are imidazolium polymers having steric hindrance at the 4-position of the imidazole moieties in the polymeric chain. The sterically-protected, N-methylated imidazolium polymers exhibit hydroxide stability in concentrated caustic solutions at elevated temperatures, such as at 100° C. and higher.
    Type: Grant
    Filed: July 29, 2017
    Date of Patent: April 12, 2022
    Assignee: Simon Fraser University
    Inventors: Steven Holdcroft, Jiantao Fan, Andrew Wright, Benjamin Britton, Thomas Weissbach, Timothy James Peckham, Jonathan William Ward
  • Patent number: 11285124
    Abstract: Compositions comprising an amino acid component including: L-histidine, L-isoleucine, L-leucine, L-lysine, L-phenylalanine, L-threonine, L-tryptophan, L-valine and L-arginine and optimized levels of L-methionine. L-tryptophan content may also be elevated and optimized, and additional amino acids including arginine, L-arginine, L-citrulline, L-carnitine and L-cysteine may optionally be present. Methods of treating muscle, wounds, surgical procedures, skin conditions and other conditions using such compositions are also provided.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: March 29, 2022
    Assignee: CALWOOD NUTRITIONALS, LLC
    Inventor: Gary Calton
  • Patent number: 11219615
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: January 11, 2022
    Assignee: RVL PHARMACEUTICALS, INC.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 11185532
    Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: November 30, 2021
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Yael Rosen, David Dangoor, Richard Fisher
  • Patent number: 11166979
    Abstract: Methods of improving athletic performance in a human, increasing the bioabsorption of the compound in a human, or of increasing the vasodilative characteristics in a human comprise administering to the human compositions and supplement formulations comprising a compound selected from the group consisting of Carnitine, Taurine, and derivative forms thereof; and a Nitrate are disclosed.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: November 9, 2021
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 11160791
    Abstract: The application provides pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and sodium chloride, wherein the composition is disposed within a plastic container as a ready to use premixture. The application also provides a premixed, ready to use sterile dexmedetomidine solution comprising dexmedetomidine and sodium chloride, wherein the solution is provided within a plastic container. Also provided are methods of providing dexmedetomidine to a subject in need of such, wherein the composition is disposed within a sealed plastic container.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Medefil, Inc.
    Inventors: Lakshmi Prasanna Kolluru, Zhiwen Guan, Sunil Potdar, Ravinder Malhotra, Pradeep Aggarwal
  • Patent number: 11103482
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: August 31, 2021
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 11000488
    Abstract: There is disclosed a method for treating pain, comprising administering an analgesic oral dosage form comprising desmetramadol substantially free of tramadol.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: May 11, 2021
    Assignee: Syntrix Biosystems Inc.
    Inventor: John A. Zebala
  • Patent number: 10952993
    Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: March 23, 2021
    Assignee: vTv Therapeutics LLC
    Inventors: Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez
  • Patent number: 10874642
    Abstract: Aspects of the invention include methods of treating ADHD, anxiety or insomnia by applying a transdermal delivery device containing a dexmedetomidine composition formulated to deliver an amount of dexmedetomidine to a subject diagnosed as having ADHD, anxiety or insomnia. In practicing methods according to certain embodiments, a transdermal delivery device having a dexmedetomidine composition is applied to a subject and is maintained in contact with the subject in a manner sufficient to deliver an amount of dexmedetomidine sufficient to treat ADHD, anxiety or insomnia in the subject. Also provided are transdermal delivery devices configured to deliver an amount of dexmedetomidine sufficient for practicing the subject methods, as well as kits containing the transdermal delivery devices.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 29, 2020
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Adchara Pongpeerapat, Amit Jain, Bret Berner, Jianye Wen, Jutaro Shudo
  • Patent number: 10822308
    Abstract: The present invention relates to processes for the preparation of eluxadoline and its intermediates.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 3, 2020
    Assignee: Sun Pharmaceutical Industries Limited
    Inventors: Kdv Jesunadh, Murad Ismail Inamdar, Mukesh Kumar Madhra
  • Patent number: 10814001
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 27, 2020
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 10793525
    Abstract: The synthesis and in vitro and in vivo anti-breast and anti-prostate cancers activities of novel C-4 heteroaryl 13-cis retinamides that modulate Mnk-eIF4E and AR signaling are discussed. In both breast and prostate cancer cell lines, these compounds induce Mnk1/2 degradation to substantially suppress eIF4E phosphorylation. In prostate cancer cells, the compounds induce degradation of both full-length androgen receptor (fAR) and splice variant AR (AR-V7) to inhibit AR transcriptional activity. The consequences of these multiple activities resulted in inhibition of cell growth and migration and induction of apoptosis. Finally and importantly, the compounds demonstrate strong in vitro and in vivo anti-breast and anti-prostate cancer activities, with no apparent host toxicities.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: October 6, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Vincent Njar, Hannah Mbatia, Vidya Ramamurthy, Senthilmurugan Ramalingam
  • Patent number: 10780079
    Abstract: The invention relates to a method for alleviating noise aversion in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof as the active ingredient. The active ingredient is preferably administered oromucosally, e.g. in the form of an oromucosal gel.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: September 22, 2020
    Assignee: ORION CORPORATION
    Inventors: Johanna Kokkonen, Mira Korpivaara, Nina Sarén
  • Patent number: 10646508
    Abstract: A method of making a composition or a dietary supplement is provided, the method comprising combining a quantity of a Nitrate with a quantity of an Amino Acid Compound, wherein the combining of the Nitrate with the Amino Acid Compound reduces a side effect or toxicity of the Nitrate. Also provided is a method of safely administering to a subject a Nitrate with a reduced side effect or toxicity, the method comprising: combining a quantity of the Nitrate with a quantity of an Amino Acid Compound in a composition or a dietary supplement, wherein the combining of the Nitrate with the Amino Acid Compound reduces the side effect or toxicity of the Nitrate; and safely administering to the subject the composition or dietary supplement comprising the Nitrate with the reduced side effect or toxicity.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 12, 2020
    Assignee: THERMOLIFE INTERNATIONAL, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10632043
    Abstract: The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 28, 2020
    Assignee: Aurobindo Pharma Ltd
    Inventors: Siva Prasad Reddy Sura, Surya Kumari Padala, Vikas Chandel, Arvind Gannimitta, Jayant Karajgi, Sivakumaran Meenakshisunderam
  • Patent number: 10603328
    Abstract: Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 31, 2020
    Assignee: CITY OF HOPE
    Inventors: Zijie Sun, David Horne, Junfeng Li, John E. Shively, Jun Xie
  • Patent number: 10583123
    Abstract: The present invention relates to the area of ATG4-related disorders. More particularly, the present invention relates to a method of treating an ATG4B-related disorder comprising a step of administering a subject with an effective amount of tioconazole. The present invention relates also to a method of increasing a subject's responsiveness to a therapy for a cancer comprising inhibition of ATG4B activity in cells; said method comprises administering the subject with an effective amount of tioconazole. The present invention also relates to a method for enhancing or inducing a response in a cancer cell consisting of cytotoxicity, chemosensitivity or starvation-sensitivity; said method comprises administering a subject with an effective amount of tioconazole to inhibit ATG4B's activity.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: March 10, 2020
    Assignee: National Tsing Hua University
    Inventors: Lee-Wei Yang, Chih-Wen Shu, Pei-Feng Liu, Kun-Lin Tsai
  • Patent number: 10555921
    Abstract: A composition and a supplement formulation includes: at least one constituent selected from the group consisting of a nitrate salt; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, Valine, Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, and Phenylalanine.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: February 11, 2020
    Assignee: ThermoLife International, LLC
    Inventors: Ronald Kramer, Alexander Nikolaidis
  • Patent number: 10543172
    Abstract: The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: January 28, 2020
    Assignee: PARAGON NORDIC AB
    Inventors: Christopher N. Hensby, Mats Silvander
  • Patent number: 10478414
    Abstract: A composition for enhancing neuroregeneration of the sciatic nerve in a mammal is provided that includes medicinally effective amounts of glycine, glutamine, and phenylalanine. In some embodiments, the glutamine can be L-glutamine and the phenylalanine can be D, L-phenylalanine. A method for treating sciatic pain is also included.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: November 19, 2019
    Inventor: Alicia Marie Wiggins
  • Patent number: 10478502
    Abstract: Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 19, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Arturo Angel, Gordon Dow
  • Patent number: 10369135
    Abstract: The present invention relates to compositions, in particular for the treatment of hyperthyreosis (also designated hyperthyroidism), especially in cats. These compositions are formulated for transdermal administration of an active substance and may, for example, be applied into the auricle (or pinna) of the cat. They comprise an active agent such as methimazole (or 2-mercapto-1-methylimidazole) or carbimazole, at least one wax, at least one fatty oil, and optionally an emulsifier. As emulsifier a nanocarrier may be used, for example. Unimolecular nanocarriers of dendritic structure are preferred, wherein the nanocarrier comprises a dendritic core and at least two shells, wherein an inner shell is coupled to the dendritic core via a first linker, and an outer shell is coupled to the inner shell via a second linker. In one embodiment, the composition is provided as a stick, in another, a semi-solid formulation in a suitable applicator which may contain one or more dosage units.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: August 6, 2019
    Assignee: DENDROPHARM GMBH
    Inventor: Sam Moré
  • Patent number: 10350190
    Abstract: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier; and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: July 16, 2019
    Assignee: DR. KENNETH ADAMS MEDICINE PROFESSIONAL CORPORATION
    Inventor: Kenneth W. Adams
  • Patent number: 10172825
    Abstract: Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABAA ionophore blocker is administered to the individual, resulting in an improvement in cognitive function of the host. The subject methods find use in a variety of different applications.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: January 8, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Craig C. Garner, Fabian J. Fernandez
  • Patent number: 10052385
    Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: August 21, 2018
    Assignee: EAGLE PHARMACEUTICALS, INC.
    Inventor: Srikanth Sundaram
  • Patent number: 10016397
    Abstract: The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 10, 2018
    Assignee: CHARITÉ—UNIVERSITAETSMEDIZN BERLIN
    Inventors: Jochen Springer, Stefan Anker, Andrew JS Coats
  • Patent number: 9814789
    Abstract: A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: November 14, 2017
    Assignee: Julius-Maximilians-Universität Würzburg
    Inventors: Bruno Allolio, Andreas Schirbel, Stefanie Hahner
  • Patent number: 9700542
    Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: July 11, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
  • Patent number: 9649713
    Abstract: A surface treating composition for copper or a copper alloy comprising an imidazole compound and means for using the composition in the soldering of electronic parts to printed wiring boards are disclosed.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 16, 2017
    Assignee: SHIKOKU CHEMICALS CORPORATION
    Inventors: Hirohiko Hirao, Noriaki Yamaji, Masato Nakanishi, Takayuki Murai
  • Patent number: 9597328
    Abstract: The present invention discloses pharmaceutical preparations for treatment of eye disorders containing an alpha 2 adrenergic agonist, to processes for producing the pharmaceutical preparations and methods for treatment of various eye disorders including dry eye and Meibomian gland dysfunction and a medicinal applicator for topical application of an alpha 2 adrenergic agonist to a subject, a package assembly for the medicinal applicator and methods of using the medicinal applicator to treat eye disorders.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 21, 2017
    Assignees: Ocugen, Inc., The Board of Trustees of the University of Illinois
    Inventors: Sandeep Jain, Uday Bhaskar Kompella, Shankar Musunuri
  • Patent number: 9446008
    Abstract: A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: September 20, 2016
    Assignee: Gruenenthal GmbH
    Inventors: Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
  • Patent number: 9394290
    Abstract: The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: July 19, 2016
    Assignee: UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN
    Inventors: Rolf Hartmann, Ulrike Hille, Christina Zimmer, Carsten A. Vock, Qingzhong Hu
  • Patent number: 9205076
    Abstract: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: December 8, 2015
    Assignee: Janssen Pharmaceutica, N.V.
    Inventors: Henry J. Breslin, Chaozhong Cai, Wei He, Robert W. Kavash
  • Patent number: 9156825
    Abstract: Provided herein are compounds according to formula (I): Provided herein is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier, and a method for providing anesthesia in a subject by administering such a pharmaceutical composition.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 13, 2015
    Assignees: THE GENERAL HOSPITAL CORPORATION, ANNOVATION BIOPHARMA, LLC
    Inventors: Douglas E. Raines, Syed Shaukat Husain, John C. R. Randle
  • Patent number: 9156792
    Abstract: Retinoic acid metabolism blocking agents (RAMBAs). The RAMBAs may be used for treatment of cancer, including breast and prostate cancers. Methods for preparing novel retinamide RAMBAs. The methods include reacting RAMBAs with terminal polar carboxylic acid group with a variety of amines in the presence of suitable coupling reagents. The retinamide RAMBAs are potent inhibitors of the growth of prostate and breast cancer cells and may be useful for the treatment of these diseases in humans.
    Type: Grant
    Filed: May 7, 2009
    Date of Patent: October 13, 2015
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Vincent C. O. Njar, Lalji K. Gediya, Aakanksha Khandelwal
  • Patent number: 9139574
    Abstract: The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: September 22, 2015
    Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.
    Inventors: Yong Wang, Cang Zhang, Xiaorong Liu, Yan Zhang, Yunyun Wang, Wenping Zhang
  • Patent number: 9062266
    Abstract: The use of imidazolium salts (I) where R1 and R3 are each independently an organic radical having 1 to 3000 carbon atoms, R2, R4 and R5 are each independently hydrogen or an organic radical having 1 to 3000 carbon atoms, X is an anion and n is the number 1, 2 or 3 as additives for fuels, especially as detergent additives for diesel fuels, as wax antisettling additives for middle distillate fuels and as lubricity improvers, and for improving the use properties of mineral and synthetic nonaqueous industrial fluids.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 23, 2015
    Assignee: BASF SE
    Inventors: Maxim Peretolchin, Ludwig Voelkel, Harald Boehnke, Markus Hansch, Boris Gaspar, Christian Seitz
  • Patent number: 9040513
    Abstract: Described is a process for preparing platinum-carbene complexes.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: May 26, 2015
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVRSITE DE STRASBOURG
    Inventors: Stéphane Bellemin-Laponnaz, Gilles Guichard, Edith Chardon
  • Publication number: 20150126436
    Abstract: The present invention provides a method of treatment of Scedosporium spp.
    Type: Application
    Filed: May 13, 2013
    Publication date: May 7, 2015
    Applicant: BIODIEM LIMITED
    Inventors: Julie Phillips, Tania Sorrell, Sharon Chen
  • Patent number: 9018240
    Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: April 28, 2015
    Assignee: Voom, LLC
    Inventor: Mark Silverberg